ArticleScientific reports2025
Socioeconomic disparities impacting breast cancer care and survival in Iran.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Public health determinants of screening accessibility, diagnostic and treatment timeliness, care adherence, and survival outcomes in breast cancer patients.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Breast cancer is the most common cancer among women. However, individuals with a lower socioeconomic status (SES) tend to experience poorer prognosis. We aimed to study disparities in diagnosis, treatment, quality of care, and survival by SES in Iran. Data from breast cancer patients at the Cancer Institute of Iran between 2014 and 2016, registered in the clinical breast cancer registry of Iran (CBCR-IR), were used. Clinical data were obtained from CBCR-IR, while follow-up data and information on SES, including 10 household assets and education level, were gathered through telephone interviews. The primary outcome was survival, determined through active follow-up. Additionally, we studied delays in treatment and the quality of care based on European Society of Breast Cancer Specialists (EUSOMA) standards. A Cox proportional hazard model was used to investigate the association between SES and survival in women with breast cancer. The inequality in breast cancer survival was analyzed using the Blinder-Oaxaca decomposition model. The 5-year overall survival rates were 87.7% (95% CI: 83.9-90.7) for low SES patients, 90.2% (95% CI: 86.7-92.8) for mid SES, and 92.1% (95% CI: 89.0-94.3) for high SES patients (log-rank test P-value = 0.077). A 3.3% gap in breast cancer mortality was observed between high and low SES patients (95% CI: 1.3-5.5), with the model explaining 2.2% of this difference. Differences in delay in treatment and stage at diagnosis accounted for 0.5% (95% CI: 0.2-0.7) and 1.8% (95% CI: 1.2-2.3) of the disparity. Breast cancer mortality is higher in low SES patients, primarily due to late diagnosis and delays in treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.